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Abstract
Genomic instability, which is a hallmark of cancer, is generally thought to occur in the middle to late stages of
tumourigenesis, following the acquisition of permissive molecular aberrations such as TP53 mutation or whole
genome doubling. Tumours with somatic POLE exonuclease domain mutations are notable for their extreme
genomic instability (their mutation burden is among the highest in human cancer), distinct mutational signature,
lymphocytic infiltrate, and excellent prognosis. To what extent these characteristics are determined by the timing of
POLE mutations in oncogenesis is unknown. Here, we have shown that pathogenic POLE mutations are detectable
in non-malignant precursors of endometrial and colorectal cancer. Using genome and exome sequencing, we
found that multiple driver mutations in POLE-mutant cancers show the characteristic POLE mutational signature,
including those in genes conventionally regarded as initiators of tumourigenesis. In POLE-mutant cancers, the
proportion of monoclonal predicted neoantigens was similar to that in other cancers, but the absolute number
was much greater. We also found that the prominent CD8+ T-cell infiltrate present in POLE-mutant cancers was
evident in their precursor lesions. Collectively, these data indicate that somatic POLE mutations are early, quite
possibly initiating, events in the endometrial and colorectal cancers in which they occur. The resulting early onset
of genomic instability may account for the striking immune response and excellent prognosis of these tumours,
as well as their early presentation.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Next-generation sequencing (NGS) technologies have
hugely advanced our understanding of the mechanisms
of tumourigenesis. The ability to analyse the entire
genome or exome at depth in large numbers of tumours
has substantially increased the list of driver genes – i.e.
those that, when mutated, promote tumour growth. It
has also revealed that such driver mutations are not
always present in the dominant tumour clone [1,2]. This
is clinically relevant, because targeting of subclonal
drivers is likely to kill only a subpopulation of tumour
cells, whereas successful targeting of clonal variants
may lead to tumour eradication. Thus, differentiating
early, clonal mutations from late, subclonal ones may
not only increase our understanding of the mechanisms
of oncogenesis, but also inform the clinical management
of patients [2].
Fundamentally, all mutations are caused, in part, by a
failure to recognize or repair defects in DNA sequence
or chromosome structure. In many cancers, this is a
consequence of specific defects in the cellular pro-
cesses responsible for maintaining genomic integrity
[3]. One recently described example is the genomic
instability caused by missense mutations in the exonu-
clease (proofreading) domains of the major replicative
DNA polymerase genes POLE and POLD1 [4]. Poly-
merase proofreading recognizes and corrects mispaired
bases incorporated during DNA replication; its per-
turbation as a result of these mutations is associated
with an exceptional number of single-nucleotide vari-
ants (SNVs) (although not indels), and a distinct muta-
tional signature typified by C:G→A:T transversions, in
which the mutated cytosine is in the context TCT, and
C:G→T:A transitions, in which the mutated cytosine is
in the context TCG [4–6]. POLE and POLD1 exonu-
clease domain mutations may occur in the germline,
where they cause polymerase proofreading-associated
polyposis – a condition characterized by intestinal poly-
posis and tumours of the colorectum and uterus, among
other organs [7]. Somatic POLE exonuclease domain
mutations (hereafter simply referred to as POLE muta-
tions) occur in sporadic tumours of the endometrium
(7–15% cases) [8,9], colorectum (1–2%) [10,11], and,
less commonly, in other cancers (although, for reasons
that are unclear, somatic POLD1 exonuclease domain
mutations are very uncommon). POLE-mutant colorec-
tal and endometrial cancers have an excellent progno-
sis [8,11–13], probably owing to a robust antitumour
immune response against the multitude of immuno-
genic neoantigens that they are predicted to harbour
[11,14,15]. Very recent reports have also suggested that
these tumours may be highly responsive to immune
checkpoint inhibition [16].
Although it is clear that somatic POLE mutation
causes a mutator phenotype [17] and acts as a can-
cer driver [4,5], several questions about its contribu-
tion to tumourigenesis remain unanswered. One of the
most important of these relates to the timing of these
mutations in cancer development. If POLE mutations
are late events, their consequences may be restricted
to a subclone of tumour cells, the targeting of which
may fail to meaningfully alter tumour behaviour. In con-
trast, if POLE mutations occur early, they could rapidly
cause a large number of clonal alterations that may
alter prognosis or response to therapy. This is particu-
larly pertinent in the light of recent data suggesting that
long-term benefit from immune checkpoint inhibition
is limited to patients whose cancers harbour neoanti-
gens in the dominant tumour clone [18]. In contrast
to germline mutations in DNA repair pathways in rare
inherited syndromes (such as the mismatch repair gene
variants that cause Lynch syndrome), the acquisition
of genomic instability in sporadic cancers has largely
been believed to be a mid-stage to late-stage event dur-
ing carcinogenesis [19]. For example, in sporadic col-
orectal cancer – a tumour type in which the molecular
progression of precancers (adenomas) to invasive car-
cinomas has been well characterized – mismatch repair
deficiency (MMR-D) or chromosomal instability occur
after initiating (epi)mutations in APC, BRAF, or KRAS,
or other events such as whole genome doubling or loss of
chromosome 18q [19–24]. Thus, in addition to its clini-
cal relevance, the demonstration that the POLE mutator
phenotype operates from the first stages of tumour ini-
tiation would also reveal a novel pathway of sporadic
tumourigenesis. A recent case report of a pathogenic
POLE mutation in a endometrial cancer and its precur-
sor [25] suggests that these mutations may occur early in
tumour development, but the single case precludes gen-
eralization of this result.
In this study, we comprehensively examined the tim-
ing of pathogenic somatic POLE mutations in sporadic
endometrial and colorectal cancers by using tumour
whole genome sequencing (WGS), public sequencing
data from The Cancer Genome Atlas (TCGA) [8,10],
and targeted sequencing of additional cohorts of cancers
and precancers.
Materials and methods
Ethical approval
Patient consent for research on tumour tissue was
obtained at the recruiting centres under local ethical
approval. Molecular analysis of anonymized tissue was
performed under Oxford Research Ethics Committee A
approval (05/Q1605/66).
Patients and tumour samples
Details of the cohorts and cases analysed in this
study are shown in supplementary material, Tables S1
and S2. Fifty-one formalin-fixed paraffin-embedded
(FFPE) endometrial cancers carrying known pathogenic
somatic POLE mutations identified in our previous
studies [12,14,26] were reviewed for the presence of a
concomitant and spatially discrete area of endometrial
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intraepithelial neoplasia (EIN) by examination of
haematoxylin and eosin (H&E)-stained slides by two
expert gynaecological pathologists (V.S. and T.B.).
An additional 389 FFPE colorectal polyps (tubular
adenomas, tubulovillous adenomas, and serrated ade-
nomas – hereafter referred to as adenomas), for which
POLE screening had not previously been performed,
were identified from 261 participants in the CORGI
study, which recruited patients with a family history
of colorectal cancer and a personal history of a col-
orectal polyp or colorectal malignancy in the absence
of a known tumour predisposition syndrome. Six fresh
frozen tumours with pathogenic somatic POLE muta-
tions (five endometrial; one colorectal) were identified
from a Leuven endometrial cancer cohort used in our
previous study [12], a prospective clinical sequencing
programme (HICF2) at the University of Oxford, or
the University of Birmingham tissue bank. TCGA
colorectal (COADREAD) [10] and endometrial (uterine
corpus endometrial carcinoma) [8] cancer data were
downloaded from the Genomic Data Commons (GDC)
Data Portal (https://portal.gdc.cancer.gov; June 2017).
An additional series of 78 FFPE endometrial cancers,
including 32 cases with pathogenic somatic POLE
mutations, were identified from the Leiden University
Medical Centre (LUMC) archives (2001–2015) [14].
Further details of the cohorts used in this study are
provided in supplementary material, Table S1. Molec-
ular analyses were performed on a single tumour or
precursor lesion region in each case.
DNA extraction
After review to confirm adequate tumour cellularity,
DNA was extracted from fresh frozen or microdissected
FFPE tumours and precursors with standard methods
[Roche FFPE-T DNA kit (F. Hoffman La Roche AG,
Basel, Switzerland), Machery Nagel Nucleospin DNA
FFPE XS (Machery Nagel, Duren, Germany)/FFPE
DNA kit, or Qiagen Blood and Tissue kit (Qiagen,
Hilden, Germany)] and resuspended in buffer or water.
DNA sequencing
Full details of the sample preparation and the sequenc-
ing methods utilized in this study are provided in
supplementary material, Supplementary materials and
methods. In brief, EINs and paired carcinomas were
sequenced for mutations in 30 cancer genes by the use
of molecular inversion probe capture, and a custom
version of the 72-gene Ion AmpliSeq Cancer Hotspot
panel v2 (including 80 genes; ThermoFisher, Waltham,
MA, USA) (supplementary material, Tables S3 and S4).
WGS of fresh frozen tumours was performed with
Illumina HiSeq (Illumina, San Diego, CA, USA), and
aligned to the reference genomewith BWAmemor Isaac
[27]. FFPE endometrial cancers from the LUMC series
were analysed by use of the Lifetech/ThermoFisher
Ion AmpliSeq Comprehensive Cancer Panel compris-
ing 409 cancer genes (http://www.lifetechnologies.com/
order/catalog/product/4477685). Mutation calling was
performed with LoFreq [28] (EINs), Mutect, Mutect2
[29], or Strelka [30] (WGS and TCGA cases), or Ion
Torrent variantCaller (EINs and LUMC FFPE tumours).
Copy number profiles were derived with Sequenza [31].
Variant annotation was performed with using Annovar
[32] or Variant Effect Predictor [33].
Definition of driver genes
Driver genes were defined according to the IntO-
Gen driver gene repository (https://www.intogen.org/
search), and included both PanCancer (Pooled_driver)
and tumour type-specific (perProject_driver) variants
(supplementary material, Tables S5 and S6) [34].
High-confidence driver mutations (defined as either
truncating mutations in genes likely to be tumour
suppressors, or recurrent missense mutations in any
endometrial or colorectal cancer-specific or pan-cancer
gene from the IntOGen set) were determined for a
subset of driver genes by manual curation, blinded to
tumour molecular characteristics.
Clonality of POLE mutations
Most (36 of 38) endometrial and colorectal cancers
with pathogenic POLE mutations were disomic at the
POLE locus (chromosome 12q24) and were informative
for clonality analysis. Of these, 20 of 22 endometrial
cancers and 12 of 14 colorectal cancers had available
copy number annotation. As all 32 of these showed
near-diploid genomes (>80% of the genome), we
assumed diploid genomes for the four remaining cases.
Mutations were filtered to include only autosomal
variants in diploid regions of the genome, called with
a depth of at least 20×. Mutation allele frequency distri-
butions were generated with the R ‘histogram’ function,
and tumour cellularity was inferred as twice the mid-
point of the allele frequency bin with the highest muta-
tion density, excluding bins with a lower bound below
an allele frequency of 0.1. These values were then sub-
jected to manual curation. The hypothesis that the muta-
tion was present in every tumour cell was tested with a
one-sided binomial test, based on the numbers of refer-
ence and variant reads at the POLEmutation site and the
inferred tumour cellularity. Specifically, for a mutation
with coverageR, in a tumour with tumour cell fractionC,
the number of variant reads was modelled as a random
variable X, with the distribution:
X ∼ Binom (R,C∕2)
In each case, we calculated the probability, p, of
finding the observed number of variant reads, v, or fewer,
P(X ≤ v). Mutations were considered to be subclonal for
p≤ 0.05.
Mutational signatures
Previously reportedmutational signatures were obtained
from http://cancer.sanger.ac.uk/cosmic/signatures/ on 1
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 283–296
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
286 D Temko et al
June 2017. The complement of mutational processes
active in the life-history of each tumour sample was
inferred by classification of mutations into 96 categories
following Alexandrov [6], and the use of non-negative
least squares regression, implemented in the R package
‘nnls’. For this analysis, only mutational signatures pre-
viously reported as active in that cancer type (endome-
trial signatures 1, 2, 5, 6, 10, 13, 14, and 26; colorectal
signatures 1, 5, 6, and 10) were used for the regression.
For cases analysed by whole exome sequencing (WES),
mutational signatures were re-scaled to exomic trinu-
cleotide frequencies. A mutational process was deemed
to have been active in the life-history of a tumour if
the associated mutational signature had a coefficient of
at least 2% of the total coefficients in the best-fitting
model. Mutations likely to be due to POLE mutation
were identified by considering mutational signatures as
multinomial probability distributions caused by specific
mutational processes. The probability of each mutation
under all mutational processes active in that tumour was
calculated, and mutations were assigned to the ‘POLE’
mutational process in cases where the probability under
that process was at least twice the probability under any
other process.
POLE consensus mutational signature scores
in driver genes
Tumour mutations were obtained from calling based
on tumour/normal .bam files (POLE-mutant cases) or
TCGAMAF files [mismatch repair-proficient (MMR-P)
and MMR-D cases], and classified into 96 categories
following Alexandrov [6]. For each tumour, the distri-
bution of mutations across the 96 types was calculated,
and re-scaled to equal trinucleotide frequencies based on
sequencing type, providing an individual tumour muta-
tional signature. Tumours were then categorized into
three groups according to POLEmutation and mismatch
repair status (i.e. POLE-mutant, MMR-P, andMMR-D),
and a consensus mutational signature was calculated for
each group as the average of the individual-tumour sig-
natures among samples in the group, weighted by the
number of mutations in each sample. The probability
of all non-silent mutations (‘non-synonymous SNV’ or
‘stopgain’) in driver genes (as defined above) under each
of the three consensus mutational signatures was then
calculated, and the ratio of the probability of each muta-
tion under the POLE consensus mutational signature
compared to that under each of the other two consensus
mutational signatures was obtained. For each individual
gene, a ‘POLE score’ was then calculated as the base 2
logarithm of the minimum value of these ratios across
all the non-silent mutations within that gene.
Immunohistochemistry
Immunohistochemistry (IHC) for CD8 was performed
as reported previously [14]. The number of CD8+ cells
was quantified for the epithelial and stromal regions
of the EIN. For the final CD8 count per case, the
mean of these regions in 10 high-power fields (HPFs)
(625× 425 μm) was calculated. A similar method was
used to quantify CD8 density in colorectal adenomas,
although the small lesion size meant that estimates were
obtained from the mean of two or three HPFs.
Clonal neoantigen prediction
We estimated the number of clonal neoantigens by
using a modification of our previously reported
algorithm [11], modified to predict peptide binding
to patient-specific human leukocyte antigen (HLA)
molecules (determined from WGS or WES data with
OptiType [35]). Neoantigens were defined as mutations
predicted to specify peptides that bound patient HLA
molecules with an affinity of <500 nM. Copy number
information was obtained from the GDC data portal, as
described above. Clonality was determined as described
above. Neoantigens were considered to be clonal if the
binomial test P value was >0.05.
Statistical analysis
Analyses were performed with R (CRAN network) or
Prism (GraphPad Software, La Jolla, CA, USA). Sta-
tistical comparison between groups was performed with
the non-parametric Mann–WhitneyU-test. All P values
were two-sided, unless otherwise specified. Statistical
significance was accepted at p< 0.05.
Results
Somatic POLE mutations are detectable in sporadic
endometrial and colorectal precancers
As somatic POLE mutations have been best charac-
terized in endometrial and colorectal cancers, we first
examined whether these mutations were present in pre-
cursors of these malignancies. Expert histopatholog-
ical review of 51 POLE-mutant endometrial cancers
revealed four with a concomitant and spatially dis-
crete area of EIN, the precursor of endometrioid car-
cinoma (supplementary material, Table S2). Microdis-
section and targeted sequencing of these lesions by
use of a 30-gene molecular inversion probe capture
NGS panel (supplementary material, Table S3), a cus-
tom 80-gene Ion Ampliseq Cancer Hotspot panel (sup-
plementary material, Table S4) and Sanger sequencing
revealed that, in all cases, the POLE mutation present in
the carcinoma was also detectable in the paired precur-
sor (Figure 1A,B; supplementary material, Table S7).
Although some other driver mutations were also shared
between the precursors and paired cancers (median of
four shared mutations per pair, relative to a median of
seven mutations per EIN and median of 10 mutations
per carcinoma), the progression fromEIN tomalignancy
was associated with both the loss (median of three muta-
tions lost in carcinomas as compared with paired EINs)
and, more frequently, gain (median of six mutations
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 283–296
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Somatic POLE mutations are early events in sporadic cancers 287
Figure 1. Pathogenic, somatic POLE mutations in precursors of endometrial and colorectal cancers. Expert histopathological review of 51
endometrial cancers with pathogenic POLE mutations revealed four with concomitant and spatially discrete areas of EIN. (A) H&E-stained
section from one case with the results of Sanger sequencing of the malignant and precursor components. (B) Targeted sequencing of
paired endometrial lesions by the use of two orthogonal NGS panels revealed that POLE mutations (bold, underlined) were present in both
EIN and carcinomas in all cases (validated by Sanger sequencing in all cases). In each case, progression of EIN to endometrial carcinoma
was associated with the gain of driver mutations, several of which were glutamic acid or arginine to stop codon mutations (E→ * or
R→ *), consistent with the POLE-mutant mutational signature (semibold). †The amount of DNA available from the EIN in case Q1-4
was insufficient for molecular inversion probe sequencing. Details of identified driver mutations are provided in supplementary material,
Table S7. (C) H&E-stained section from colorectal adenoma with the results of Sanger sequencing and allelic discrimination polymerase
chain reaction for the wild-type G allele and mutant T allele.
gained in carcinomas as compared with paired EINs)
of driver mutations (Figure 1A,B; supplementary mate-
rial, Table S7). Notably, many of the driver mutations
gained were replacements of a glutamic acid or argi-
nine codon with a nonsense codon (E→ * or R→ *),
consistent with the characteristic mutational bias asso-
ciated with POLE mutation (C:G→A:T transversions,
in which the mutated cytosine is in the context TCT, and
C:G→T:A transitions, in which the mutated cytosine is
in the context TCG) [4–6] (Figure 1B; supplementary
material, Table S7).
We were unable to perform a corresponding anal-
ysis of colorectal tumours, because a residual pre-
cursor is uncommon in colorectal carcinomas. How-
ever, screening of 389 colorectal adenomas from 261
patients revealed three (0.8% adenomas; 1.1% patients)
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with somatic POLE mutations (Figure 1C), a frequency
concordant with that found in colorectal cancers [11].
Unfortunately, the limited amount of DNA available
from these lesions precluded analysis of other driver
mutations.
Mutational landscape and driver gene alterations
suggest that somatic POLE mutation is an early
event in sporadic endometrial and colorectal
cancers
To further investigate the timing of POLE mutations
and their consequences for tumour development, we
performed WGS on six cancers (five endometrial; one
colorectal), all of which harboured the most common
pathogenic POLE exonuclease domain variant – a pro-
line to arginine substitution at codon 286 (POLEP286R)
(Figure 2A). Each showed a substantially elevated
mutation burden (122–731 mutations/Mb), and char-
acteristic preponderance of C:G→A:T substitutions
in the context TCT (Figure 2A,B; supplementary
material, Table S8 and Figure S1) [6]. In keeping
with their early occurrence, both the POLE muta-
tions themselves, and other mutations consistent with
the known POLE mutational signature (see Materi-
als and methods, ‘Mutational signatures’), appeared
to be clonal in all six cases (Figure 2C). This was
also the case in 17 of 17 endometrial cancers and
12 of 13 colorectal cancers with pathogenic POLE
mutations from the TCGA series (supplementary
material, Figures S2 and S3). This analysis showed
that POLE mutations were unlikely to occur as late
events after the most recent common ancestor in cancer
evolution.
We next examined the timing of POLE mutations
in carcinogenesis in more detail by analysis of driver
genes, including some that are known to be usually
mutated early in the pathogenesis of endometrial or col-
orectal cancer. To assess the likelihood of mutations in
these genes being secondary to an earlier POLE muta-
tion, we developed a metric to score them according
to the probability that they were caused by the muta-
tional process dominant in POLE-mutant cancers (pre-
sumably caused by the POLE mutation itself), rather
than the mutational processes operative in other tumours
(see Materials and methods, ‘POLE consensus muta-
tional signature scores in driver genes’ for details). For
this analysis, we combined our cohort of POLE-mutant
tumours with POLE-mutant cases from TCGA, using
MMR-P and MMR-D TCGA cases as comparators.
Strikingly, in POLE-mutant tumours, almost all known
cancer driver genes showed evidence of the POLE con-
sensus mutational signature, with the notable excep-
tion of POLE itself (Figures 3 and 4; supplementary
material, Tables S8–S10 and Figures S4 and S5), con-
sistent with the postulate that the POLE signature is
a direct effect of the polymerase proofreading muta-
tion. In contrast, MMR-P and MMR-D tumours rarely
showed evidence of the POLE consensus mutational
signature (Figures 3 and 4; supplementary material,
Tables S8–S10). In total, among 206 endometrial and/or
colorectal cancer driver genes examined in the cases
from the combined endometrial and colorectal cancer
cohorts, 50% (1065/2118) of those in POLE-mutant
samples had a POLE signature score of>0, as compared
with 14% (628/4427) in MMR-D and MMR-P cancers
(p< 1× 10–26).
To minimize the possibility of confounding by
non-pathogenic mutations in the complete set of driver
genes, we repeated these analyses considering only
manually curated, high-confidence pathogenic muta-
tions, and obtained similar results (p< 1× 10–26;
supplementary material, Figures S6 and S7). As muta-
tion of the tumour suppressor genes PTEN and APC
are well recognized as early, if not initiating, events in
the pathogenesis of endometrial and colorectal cancers,
respectively, we specifically examined whether somatic
variants in these genes varied according to tumourPOLE
mutation status. Among high-confidence pathogenic
PTEN mutations in endometrial cancers, the proportion
with POLE consensus mutational signature scores of
>0 was substantially and significantly greater among
POLE-mutant cases than among MMR-P and MMR-D
tumours [10 of 14 (71.4%) versus 14 of 82 (17.1%)
mutations, respectively; p= 7.8× 10–3, Fisher’s exact
test]. Analysis of high-confidence pathogenic APC
mutations in colorectal cancers revealed similar results
[corresponding proportions nine of 14 (64.3%) versus
10 of 69 (14.5%) mutations; p= 0.012, Fisher’s exact
test].
Further analysis of these cohorts and of targeted
sequencing data from an additional series of endometrial
cancers from the LUMC, including 32 POLE-mutant
tumours, confirmed the over-representation of E→ *,
R→ * and arginine to glutamine substitutions (R→Q)
among POLE-mutant cases, concordant with the results
from the paired endometrial lesions and consistent with
the known trinucleotide bias of the POLE mutational
signature (supplementary material, Figures S8–S10
and Tables S7–S11). Interestingly, this was evident
not only in well-characterized driver genes such as
PTEN in endometrial cancer and APC in colorectal
cancer, as noted above, but also in recurrent, clonal
driver mutations that are rarely found in that tumour
type. For example, in the combined TCGA/LUMC
endometrial cancer cohorts, truncating mutations in the
tumour suppressors APC, NF1 and RB1 were very rare
in POLE-wild-type tumours (1.1%, 1.5%, and 1.5%,
respectively), but common among POLE-mutant cases
(38.8%, 34.7%, and 34.7%, respectively; p< 0.001 for
each comparison, Fisher’s exact test), in which they
almost invariably occurred at glutamic acid or arginine
codons (supplementary material, Figures S8–S10, and
Tables S9 and S11).
Collectively, these data suggest that somatic POLE
mutation occurs early in endometrial and colorectal
cancers, and that its attendant mutator phenotype defines
a distinct pathway of carcinogenesis from the initial
stages of this process.
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Figure 2. WGS of cancers with POLE mutations. (A) Mutation burden and SNV type determined by WGS of five endometrial cancers (ECs)
(Oxf001, POLE_040, POLE_049, POLE_072, and POLE_147) and one colorectal cancer (CRC) (Bir001) with somatic POLEP286R mutations. (B)
Relative proportions of SNV mutations according to trinucleotide context averaged across the six POLE-mutant cases. The upper panel
shows the unscaled proportions across the whole genome, and the lower panel shows the inferred mutational signature in a hypothetical
genome for which all trinucleotide frequencies are represented in equal proportions. High-resolution versions are provided in supplementary
material, Figure S1. (C) Frequency histograms and kernel density plots showing the variant allele fraction (VAF) of all SNV mutations, and
SNVs that are probably due to POLE mutation (POLE ). POLE mutations and other driver gene mutations are highlighted by arrows (details
are provided in supplementary material, Table S8). Only mutations in diploid regions of autosomes, and with a coverage of >20×, are
shown. The relatively low proportion of SNVs categorized as being due to POLE mutation reflects the stringency of the classification used
(see Materials and methods, ‘Mutational signatures’). Vertical red lines indicate the clonal peaks used to calculate cellularity.
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Figure 3. POLE signature mutations in endometrial cancer driver genes. Heatmaps show the modelled probability that mutations in
endometrial cancer driver genes (defined on the basis of IntOGen – see Materials and methods, ‘Definition of driver genes’; supplementary
material, Table S5) were due to a prior POLE mutation. Results are shown for samples with a pathogenic POLE mutation and MMR-D and
MMR-P comparators. Each non-synonymous mutation in a driver gene was assigned a probability that it was caused by the mutational
process that generates the distinct POLE mutational signature, rather than by the mutational processes responsible for the consensus
mutational signatures of POLE-wild-type MMR-P and MMR-D tumours (see Materials and methods, ‘POLE consensus mutational signature
scores in driver genes’, for details. For each gene/sample combination, a ‘POLE score’ was then calculated as the minimum value of these
ratios, and plotted as a heatmap. Scores are shown for both individual POLE-mutant tumours and the combined POLE-mutant subgroup;
results for tumours within the POLE-wild-type MMR-P and POLE-wild-type MMR-D subgroups are combined for clarity. Scores for POLE
itself are shown for reference. Details of mutations are provided in supplementary material, Tables S8 and S9. A high-resolution version of
this figure is provided as supplementary material, Figure S4.
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Figure 4. POLE signature mutations in colorectal cancer driver genes. Corresponding heatmaps to those in Figure 3 show the results
for known colorectal cancer driver genes (defined on the basis of IntOGen – see Materials and methods, ‘Definition of driver genes’;
supplementary material, Table S4). Details of mutations are provided in supplementary material, Tables S8 and S10. A high-resolution
version of this figure is provided as supplementary material, Figure S5.
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Somatic POLE mutations are associated with
a prominent T-cell infiltrate in both precancerous
and cancerous lesions
Somatic POLE mutations in endometrial and col-
orectal cancers are associated with enhanced tumour
immunogenicity and a favourable prognosis [11,14,15].
We speculated that the early acquisition of somatic
POLE mutations would cause rapid acquisition of
mutations, some of which would produce neoantigens
capable of eliciting an antitumour immune response.
Consistent with this prediction, all POLE-mutant EINs
showed a prominent CD8+ infiltrate (Figure 5A), which
was significantly greater than that in POLE-wild-type
EINs (median 59.4 versus 14.8 CD8+ cells per HPF;
p= 0.029, Mann–Whitney U-test), and exceeded that
observed in the POLE-wild-type endometrial carci-
nomas, although this difference was not statistically
significant (median 59.4 versus 24.7 CD8+ cells per
HPF; p= 0.11) (Figure 5B). The increased CD8+ cell
density in POLE-mutant EINs could not obviously be
explained by other factors such as patient age, or the
stage or grade of the paired carcinoma (supplemen-
tary material, Table S2). In contrast, the differences in
CD8+ density between EINs and paired carcinomas
among both POLE-wild-type and POLE-mutant cases
were less marked (median 14.8 versus 24.7, p= 0.34,
and 59.4 versus 116.9, p= 0.11, respectively). The
single POLE-mutant colorectal adenoma for which
IHC was possible also showed a dense CD8+ infil-
trate (154.9 versus median 34.0 CD8+ cells per HPF)
(Figure 5A,B).
Somatic POLE mutations in colorectal cancer
are associated with an enhanced predicted clonal
neoantigen burden
Recent data have shown that the presence of predicted
neoantigens within the major tumour clone correlates
with the benefit of immune checkpoint inhibitor therapy
[18]. As the limited amount of FFPE-derived DNA
from precursor lesions was inadequate for clonal-
ity analysis and neoantigen prediction, we examined
predicted neoantigen clonality in a subset of TCGA
colorectal cancers including MMR-P, MMR-D and
POLE-mutant subtypes, broadly matched for patient
age and tumour stage. We used an approach similar to
that in our previous reports [11,14], modified to incor-
porate patient-specific HLA haplotypes obtained with
OptiType [35] and estimates of tumour clonality derived
from analysis of variant allele frequencies (see Mate-
rials and methods, ‘Clonal neoantigen prediction’).
Analysis of our combined cohort with this pipeline
confirmed that POLE-mutant colorectal cancers har-
boured a substantially greater number and density of
predicted clonal neoantigens (0.12/Mb) than tumours
lacking POLE mutations, including both MMR-P cases
(0.0029/Mb; p= 0.0002, Mann–Whitney U-test) and
hypermutated MMR-D cases (0.044/Mb; p= 0.03)
(Figure 6; supplementary material, Figure S11).
Discussion
In this article, we have presented multiple lines of evi-
dence to show that pathogenic, somatic POLEmutations
are usually early and, as far as we can detect, initiat-
ing events in endometrial and colorectal tumourigen-
esis. We show that the acquisition of POLE mutation
causes a distinct pattern of mutations in cancer driver
genes, a substantially increased mutation burden, and an
enhanced immune response, detectable even in precan-
cerous lesions. Furthermore, we show that early somatic
POLE mutations are likely to cause an enrichment of
clonal neoantigens that may explain the good prognosis
of cancers carrrying these variants, and their excellent
response to immune checkpoint inhibitors.
APC mutation has traditionally been regarded as
the initiating event in sporadic colorectal cancers that
develop along the canonical pathway [19], and PTEN
mutation is thought to play a similar role in sporadic
endometrioid endometrial cancers [36]. Our evidence
suggests that, in sporadic colorectal and endometrial
cancers with pathogenic somatic POLE mutations, the
POLE mutation is antecedent to either of these events.
The consequent mutator phenotype that it causes influ-
ences the types of mutation in these genes and those
of the other earliest driver mutations in these cancers,
as well as determining their overall mutational land-
scape [6]. Whether any of these POLE-induced driver
mutations represent targetable alterations will be an
important topic for future research. Similarly, although
the increased burden of predicted clonal neoantigens
in POLE-mutant tumours may explain their enhanced
immunogenicity, further work is required to understand
the molecular factors that determine this and its thera-
peutic implications. A further intriguing possibility is
that the mutator phenotype and mutational bias drive
cancers into an evolutionary cul-de-sac of suboptimal
fitness. The presence of APC mutations as an alternative
to CTNNB1 mutations in some POLE-mutant endome-
trial cancers is an exemplar, and there are likely to be
others, such as NF1 and RB1 mutations in endome-
trial cancer and atypical (Q61P, K117N, and A146T)
KRAS mutations in colorectal cancer. Examination of
this hypothesis by comparing the oncogenic effects of
these uncommon mutations with those of more typi-
cal variants in model systems would be of considerable
interest.
Our data add to the expanding body of evidence
suggesting that the effects of genomic instability in
cancer depend upon both its severity and its timing. For
example, upregulation of APOBEC cytosine deaminase
enzymes is common in many types of cancer, resulting
in an increased mutation rate and characteristic mutation
spectrum [6]. However, APOBEC overexpression often
occurs as a late event in advanced tumours, and causes a
more modest mutator phenotype than POLE mutations
[2,6]. Speculatively, these features may explain why
the impact of APOBEC on prognosis appears to be
more variable than that of POLE mutation [37,38]. The
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Figure 5. T-cell infiltrate in POLE-mutant precursor lesions. (A) Representative immunohistochemical images for the cytotoxic T-cell marker
CD8 in EINs and paired concomitant endometrioid adenocarcinomas and in colorectal adenomas according to POLE mutation status.
(B) Quantification of CD8+ infiltrate density (number of CD8+ cells per HPF calculated as the mean of 10 HPFs) in POLE-wild-type and
POLE-mutant paired EIN and endometrial carcinoma (EC) (n= 4 EIN–carcinoma pairs for each genotype) and in POLE-wild-type and
POLE-mutant colorectal adenomas (Ad) (n= 5 POLE-wild-type lesions, and the single POLE-mutant adenoma informative for analysis).
Symbols (square, circle, triangle and diamond) correspond to paired EIN and endometrial carcinomas for POLE-wild-type (open symbols)
and POLE-mutant (closed symbols) cases. For colorectal adenomas, open and closed triangles correspond to unpaired POLE-wild-type
and POLE-mutant adenomas respectively. Statistical comparisons in (B) were performed with an unadjusted Mann–Whitney U-test. Mut,
mutant; ns, not significant; WT, wild type.
early acquisition of somaticPOLEmutations in sporadic
cancers may also help to explain their association with
young age at diagnosis, given the prediction that the
early gain of a mutator phenotype will accelerate the
process of malignant transformation [39].
Our study has limitations. The number of precursor
lesions informative for detailed analysis was limited,
in keeping with the relative rarity of POLE mutations
in endometrial cancer, and the frequency with which
precancerous and cancerous lesions occur in the same
tumour section. Moreover, although the spatial separa-
tion of the precancerous and cancerous compartments,
and the discordance in molecular alterations between
the two components in each case, suggest otherwise,
we cannot exclude the possibility that the apparent
precursor lesion is, in fact, adenocarcinoma colonizing
endometrial glands. It will therefore be important to
validate our results in additional cohorts, although
we note that a very recent study has documented a
pathogenic POLE mutation in an endometrial cancer
precursor [25]. Furthermore, all of our results are based
on the analysis of a single sample of each cancer, mean-
ing that the effects of intratumour heterogeneity on
the pattern of driver mutations and clonal neoantigens
in POLE-mutant tumours require further definition.
However, the absence of multiregion sequencing is
unlikely to have confounded the principal conclusions
of our study regarding the timing of these pathogenic
mutations in cancers.
In summary, we show that pathogenic, somatic POLE
mutations are early, quite possibly initiating, events in
sporadic cancers, and strongly shape subsequent tumour
evolution. Our observation provides further insights into
the distinct biology of these tumours, and may help to
explain their increased immunogenicity and excellent
prognosis.
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Figure 6. Clonality of predicted neoantigens in POLE-mutant colorectal cancers. Neoantigens were predicted on the basis of the binding
affinity of mutant peptides for patient class I HLA molecules, and were assigned clonal or subclonal status (see Materials and methods,
‘Clonality of POLE mutations’). The numbers of clonal and subclonal neoantigens for POLE-wild-type MMR-P, POLE-wild-type MMR-D
and POLE-mutant colorectal cancers from the TCGA series are shown. Cases in each molecular subgroup were selected to provide broadly
similar proportions of disease stages and patient ages: molecular subgroups did not differ significantly in either parameter. Comparison of
the clonal neoantigen burden between groups was performed with an unadjusted Mann–Whitney U-test.
Acknowledgements
We thank Michelle Osse, Natalja ter Haar, Nienke
Solleveld-Westerink and Dina Ruano for help with
performing and interpreting the Ion AmpliSeq Can-
cer Hotspot Panel. We would also like to thank the
patients who gave consent for the molecular analy-
sis of their tumours reported in this study. The results
published here include data generated by The Cancer
Genome Atlas project funded by the NCI and NIH (can-
cergenome.nih.gov); we would like to thank the many
patients and researchers who contributed to this study.
Funding for this study was provided by: Cancer
Research UK (C6199/A10417 and C399/A2291),
the European Union Seventh Framework Programme
(FP7/207-2013) grant 258236 collaborative project
SYSCOL, European Research Council project EVO-
CAN, the Dutch Cancer Society, Research Fund
Flanders (F.W.O.) grant no. G.0827.13, the Medical
Research Council, the Wellcome Trust and Department
of Health as part of a Health Innovation Challenge
Fund grant (R6-388), the National Institute for Health
Research (NIHR) Oxford Biomedical Research Cen-
tre, Ovarian Cancer Action and core funding to the
Wellcome Trust Centre for Human Genetics from the
Wellcome Trust (090532/Z/09/Z). The views expressed
are those of the authors and not necessarily those of
the NHS, the NIHR, the Department of Health or the
Wellcome Trust.
DT is funded by an EPSRC doctoral training grant
via CoMPLEX. MG is funded by a Studentship
from the Wellcome Trust. TB is funded by the
Dutch Cancer Society Young Investigator Grant
10418. ADB acknowledges funding from the Well-
come Trust (102732/Z/13/Z), Cancer Research UK
(C31641/A23923) and the Medical Research Coun-
cil (MR/M016587/1). FA is a senior researcher for
the F.W.O. TG is a Cancer Research UK Career
Development Fellow (A19771) and a Wellcome Trust
Investigator (202778/Z/16/Z). DNC is funded by a
Health Foundation/Academy of Medical Sciences
Clinician Scientist Fellowship.
The cost of open access publication was provided by
core funding to the Wellcome Trust Centre for Human
Genetics from the Wellcome Trust (090532/Z/09/Z).
Author contributions statement
DT, TG, DNC, and IT designed the study. DT, IVG, ER,
SM, MB, LC, CP, JD, AB, CS, JM, VC, MR, AA, FA,
DL, VS, and TB collected data. DT, IVG, ER, MG, LC,
CP, AMB,MW, MR, JT, AS, VS, TB, TG, DNC, and IT
analysed data. DT, TG, DNC, and IT interpreted data.
DNC and IT wrote the manuscript.
References
1. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape
and significance across 12 major cancer types. Nature 2013; 502:
333–339.
2. McGranahan N, Favero F, de Bruin EC, et al. Clonal status of
actionable driver events and the timing of mutational processes in
cancer evolution. Sci Transl Med 2015; 7: 283ra254.
3. Tubbs A, Nussenzweig A. Endogenous DNA damage as a source of
genomic instability in cancer. Cell 2017; 168: 644–656.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 283–296
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Somatic POLE mutations are early events in sporadic cancers 295
4. Rayner E, van Gool IC, Palles C, et al. A panoply of errors: poly-
merase proofreading domain mutations in cancer. Nat Rev Cancer
2016; 16: 71–81.
5. Shinbrot E, Henninger EE,Weinhold N, et al.Exonuclease mutations
in DNA polymerase epsilon reveal replication strand specific muta-
tion patterns and human origins of replication.Genome Res 2014; 24:
1740–1750.
6. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of muta-
tional processes in human cancer. Nature 2013; 500: 415–421.
7. Palles C, Cazier JB, Howarth KM, et al. Germline mutations affect-
ing the proofreading domains of POLE and POLD1 predispose to
colorectal adenomas and carcinomas. Nat Genet 2013; 45: 136–144.
8. The Cancer Genome Atlas Network. Integrated genomic characteri-
zation of endometrial carcinoma. Nature 2013; 497: 67–73.
9. Church DN, Briggs SE, Palles C, et al. DNA polymerase epsilon and
delta exonuclease domain mutations in endometrial cancer.HumMol
Genet 2013; 22: 2820–2828.
10. The Cancer Genome Atlas Network. Comprehensive molecular char-
acterization of human colon and rectal cancer. Nature 2012; 487:
330–337.
11. Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE
proofreading domain mutation, immune response, and prognosis in
colorectal cancer: a retrospective, pooled biomarker study. Lancet
Gastroenterol Hepatol 2016; 1: 207–216.
12. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of
POLE proofreading mutations in endometrial cancer. J Natl Cancer
Inst 2015; 107: 402.
13. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease
domain mutation predicts long progression-free survival in grade 3
endometrioid carcinoma of the endometrium. Gynecol Oncol 2014;
134: 15–19.
14. van Gool IC, Eggink FA, Freeman-Mills L, et al. Pole proofreading
mutations elicit an antitumor immune response in endometrial cancer.
Clin Cancer Res 2015; 21: 3347–3355.
15. Howitt BE, Shukla SA, Sholl LM, et al. Association of poly-
merase e-mutated and microsatellite-instable endometrial cancers
with neoantigen load, number of tumor-infiltrating lymphocytes, and
expression of PD-1 and PD-L1. JAMA Oncol 2015; 1: 1319–1323.
16. Santin AD, Bellone S, Buza N, et al. Regression of
chemotherapy-resistant polymerase epsilon (POLE) ultra-mutated
and MSH6 hyper-mutated endometrial tumors with nivolumab. Clin
Cancer Res 2016; 22: 5682–5687.
17. Kane DP, Shcherbakova PV. A common cancer-associated DNA
polymerase ε mutation causes an exceptionally strong mutator phe-
notype, indicating fidelity defects distinct from loss of proofreading.
Cancer Res 2014; 74: 1895–1901.
18. McGranahan N, Furness AJ, Rosenthal R, et al. Clonal neoantigens
elicit T cell immunoreactivity and sensitivity to immune checkpoint
blockade. Science 2016; 351: 1463–1469.
19. Fearon ER.Molecular genetics of colorectal cancer. Annu Rev Pathol
2011; 6: 479–507.
20. Kambara T, Simms LA, Whitehall VL, et al. BRAF mutation is
associated with DNA methylation in serrated polyps and cancers of
the colorectum. Gut 2004; 53: 1137–1144.
21. Minoo P, Moyer MP, Jass JR. Role of BRAF-V600E in the serrated
pathway of colorectal tumourigenesis. J Pathol 2007; 212: 124–133.
22. Fujiwara T, Bandi M, Nitta M, et al. Cytokinesis failure generating
tetraploids promotes tumorigenesis in p53-null cells. Nature 2005;
437: 1043–1047.
23. Thompson SL, Compton DA. Proliferation of aneuploid human cells
is limited by a p53-dependent mechanism. J Cell Biol 2010; 188:
369–381.
24. Burrell Ra, McClelland SE, Endesfelder D, et al. Replication stress
links structural and numerical cancer chromosomal instability.
Nature 2013; 494: 492–496.
25. Miyamoto T, Ando H, Asaka R, et al. Mutation analysis by
whole exome sequencing of endometrial hyperplasia and carci-
noma in one patient: abnormalities of polymerase epsilon and the
phosphatidylinositol-3 kinase pathway. J Obstet Gynaecol Res 2018;
44: 179–183.
26. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identi-
fying targetable pathways for high-risk endometrial cancer; a Trans-
PORTEC initiative. Mod Pathol 2015; 28: 836–844.
27. Raczy C, Petrovski R, Saunders CT, et al. Isaac: ultra-fast
whole-genome secondary analysis on Illumina sequencing platforms.
Bioinformatics 2013; 29: 2041–2043.
28. Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequence-quality
aware, ultra-sensitive variant caller for uncovering cell-population
heterogeneity from high-throughput sequencing datasets. Nucleic
Acids Res 2012; 40: 11189–11201.
29. Cibulskis K, Lawrence MS, Carter SL, et al. Sensitive detection
of somatic point mutations in impure and heterogeneous cancer
samples. Nat Biotechnol 2013; 31: 213–219.
30. Saunders CT, Wong WS, Swamy S, et al. Strelka: accurate somatic
small-variant calling from sequenced tumor–normal sample pairs.
Bioinformatics 2012; 28: 1811–1817.
31. Favero F, Joshi T, Marquard AM, et al. Sequenza: allele-specific
copy number and mutation profiles from tumor sequencing data. Ann
Oncol 2015; 26: 64–70.
32. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data. Nucleic
Acids Res 2010; 38: e164.
33. McLaren W, Gil L, Hunt SE, et al. The Ensembl Variant Effect
Predictor. Genome Biol 2016; 17: 122.
34. Gonzalez-Perez A, Perez-Llamas C, Deu-Pons J, et al.
IntOGen-mutations identifies cancer drivers across tumor types. Nat
Methods 2013; 10: 1081–1082.
35. Szolek A, Schubert B, Mohr C, et al. OptiType: precision HLA
typing from next-generation sequencing data. Bioinformatics 2014;
30: 3310–3316.
36. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression
as a diagnostic marker for the earliest endometrial precancers. J Natl
Cancer Inst 2000; 92: 924–930.
37. Leonard B, Starrett GJ, Maurer MJ, et al. APOBEC3G expression
correlates with T-cell infiltration and improved clinical outcomes in
high-grade serous ovarian carcinoma. Clin Cancer Res 2016; 22:
4746–4755.
38. Sieuwerts AM, Willis S, Burns MB, et al. Elevated APOBEC3B
correlates with poor outcomes for estrogen-receptor-positive breast
cancers. Horm Cancer 2014; 5: 405–413.
39. Beckman RA, Loeb LA. Efficiency of carcinogenesis with and with-
out a mutator mutation. Proc Natl Acad Sci U S A 2006; 103:
14140–14145.
*40. Findlay JM, Castro-Giner F, Makino S, et al.Differential clonal evo-
lution in oesophageal cancers in response to neo-adjuvant chemother-
apy. Nat Commun 2016; 7: 11111.
*Cited only in supplementary material.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 283–296
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
296 D Temko et al
SUPPLEMENTARY MATERIAL ONLINE
Supplementary materials and methods
Supplementary figure legends
Figure S1. Relative proportion of SNV mutations according to trinucleotide context in six POLE-mutant tumour genomes (high resolution image)
Figure S2. Clonality of POLE mutations and mutational processes in TCGA endometrial cancers
Figure S3. Clonality of POLE mutations and mutational processes in TCGA colorectal cancers
Figure S4. POLE signature mutations in endometrial cancer driver genes (high resolution image)
Figure S5. POLE signature mutations in colorectal cancer driver genes (high resolution image)
Figure S6. POLE signature in high-confidence endometrial cancer driver mutations
Figure S7. POLE signature in high-confidence colorectal cancer driver mutations
Figure S8. Driver mutations in TCGA endometrial cancers
Figure S9. Driver mutations in TCGA colorectal cancers
Figure S10. Driver mutations in LUMC endometrial cancers
Figure S11. Clonality of neoantigens in TCGA colorectal cancers
Table S1. Cohorts analysed and molecular analyses performed
Table S2. Details of cases used for molecular analyses
Table S3. Genes included in custom molecular inversion probe panel
Table S4. Genes included in custom Ion AmpliSeq Cancer Hotspot Panel
Table S5. List of IntOGen endometrial cancer driver genes used in this study
Table S6. List of IntOGen colorectal cancer driver genes used in this study
Table S7. Driver mutations detected in paired endometrial intraepithelial neoplasias (EIN) and endometrial carcinomas
Table S8. Driver mutations in POLE-mutant cancers analysed by whole genome sequencing
Table S9. Driver mutations in TCGA endometrial cancers by tumour molecular subgroup
Table S10. Driver mutations in TCGA colorectal cancers by tumour molecular subgroup
Table S11. Driver mutations in endometrial cancers analysed by Ion Ampliseq Comprehensive Cancer Panel
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 245: 283–296
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
